Amgen disses drug pricing bill, while amping $4B rare drug company deal and upcoming Humira biosim launch

Add Amgen CEO Bob Bradway to the chorus of pharma CEOs lamenting the pending drug pricing legislation in the US Senate. “For some time, we’ve been advocating for reforms that respect innovation and provide improved access to it. The proposed bill does neither. The bill will impose price controls, and…

...

Click to view original post